Review





Similar Products

99
Psychology Software Tools test sequence
Test Sequence, supplied by Psychology Software Tools, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/test+sequence/E-Prime/pmc12928708-80-12-19
Average 99 stars, based on 1 article reviews
test sequence - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier

86
Karius Inc karius test sequencing
Summary of enrolled plasma <t>mcfDNA-sequencing</t> studies published from 1st January 2015 to 28th February 2025. USA*: Refer to. , , , , China*: Refer to. , Germany*:Refer to.
Karius Test Sequencing, supplied by Karius Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/test+sequence/karius+spectrum/pmc12968814-148-15-15
Average 86 stars, based on 1 article reviews
karius test sequencing - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

86
Karius Inc metagenomic sequencing based test
Summary of enrolled plasma <t>mcfDNA-sequencing</t> studies published from 1st January 2015 to 28th February 2025. USA*: Refer to. , , , , China*: Refer to. , Germany*:Refer to.
Metagenomic Sequencing Based Test, supplied by Karius Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/test+sequence/generation+next+sequencing/pmc12955461-11-71-74
Average 86 stars, based on 1 article reviews
metagenomic sequencing based test - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

97
Foundation Medicine Inc next generation sequencing tests
Summary of enrolled plasma <t>mcfDNA-sequencing</t> studies published from 1st January 2015 to 28th February 2025. USA*: Refer to. , , , , China*: Refer to. , Germany*:Refer to.
Next Generation Sequencing Tests, supplied by Foundation Medicine Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/test+sequence/FoundationOne+Liquid+CDx/pm41686740-588-10-8
Average 97 stars, based on 1 article reviews
next generation sequencing tests - by Bioz Stars, 2026-10
97/100 stars
  Buy from Supplier

86
Minitab Inc test sequence
Summary of enrolled plasma <t>mcfDNA-sequencing</t> studies published from 1st January 2015 to 28th February 2025. USA*: Refer to. , , , , China*: Refer to. , Germany*:Refer to.
Test Sequence, supplied by Minitab Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/test+sequence/sequence+test/10__1016_slash_j__wds__2026__100274-128-18-22
Average 86 stars, based on 1 article reviews
test sequence - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

86
Quest Diagnostics notch3 cadasil sequencing test
Summary of enrolled plasma <t>mcfDNA-sequencing</t> studies published from 1st January 2015 to 28th February 2025. USA*: Refer to. , , , , China*: Refer to. , Germany*:Refer to.
Notch3 Cadasil Sequencing Test, supplied by Quest Diagnostics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/test+sequence/cadasil+notch3+sequencing+test/us12496296-503-12-10
Average 86 stars, based on 1 article reviews
notch3 cadasil sequencing test - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

86
Karius Inc bal fluid mcfdna sequencing test report
Flow diagram depicting patient and sample selection for the comparison of <t>BAL</t> fluid <t>mcfDNA</t> <t>sequencing</t> with the Karius® test and standard of care testing.
Bal Fluid Mcfdna Sequencing Test Report, supplied by Karius Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/test+sequence/mcfdna+sequencing/med_rxiv__2025__11__05__25339543-51-4-28
Average 86 stars, based on 1 article reviews
bal fluid mcfdna sequencing test report - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

86
Invitae Inc next generation sequencing ngs diagnostic test
Flow diagram depicting patient and sample selection for the comparison of <t>BAL</t> fluid <t>mcfDNA</t> <t>sequencing</t> with the Karius® test and standard of care testing.
Next Generation Sequencing Ngs Diagnostic Test, supplied by Invitae Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/test+sequence/generation+next+sequencing/pmc12659938-53-10-15
Average 86 stars, based on 1 article reviews
next generation sequencing ngs diagnostic test - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

Image Search Results


Summary of enrolled plasma mcfDNA-sequencing studies published from 1st January 2015 to 28th February 2025. USA*: Refer to. , , , , China*: Refer to. , Germany*:Refer to.

Journal: Infection and Drug Resistance

Article Title: Refining the Clinical Utility of Plasma Microbial Cell-Free DNA Sequencing in High-Risk Population of Infection: A Narrative Review

doi: 10.2147/IDR.S562107

Figure Lengend Snippet: Summary of enrolled plasma mcfDNA-sequencing studies published from 1st January 2015 to 28th February 2025. USA*: Refer to. , , , , China*: Refer to. , Germany*:Refer to.

Article Snippet: Christians et al developed a workflow that enriches ultrashort and rare mcfDNA fragments prior to Karius test sequencing, enabling the identification of key AMR genes, such as SCCmec, mecA, mecC, vanA, vanB, blaCTX-M , and blaKPC , with diagnostic yields ranging from 56.8% to 83.3%.

Techniques: Clinical Proteomics, Sequencing

The refinement strategy of clinical utility of plasma mcfDNA sequencing and prospective. *Co-mNGS Integration (Plasma + Blood Cell DNA): Cost-effectiveness should be further investigated, particularly in resource-limited settings.

Journal: Infection and Drug Resistance

Article Title: Refining the Clinical Utility of Plasma Microbial Cell-Free DNA Sequencing in High-Risk Population of Infection: A Narrative Review

doi: 10.2147/IDR.S562107

Figure Lengend Snippet: The refinement strategy of clinical utility of plasma mcfDNA sequencing and prospective. *Co-mNGS Integration (Plasma + Blood Cell DNA): Cost-effectiveness should be further investigated, particularly in resource-limited settings.

Article Snippet: Christians et al developed a workflow that enriches ultrashort and rare mcfDNA fragments prior to Karius test sequencing, enabling the identification of key AMR genes, such as SCCmec, mecA, mecC, vanA, vanB, blaCTX-M , and blaKPC , with diagnostic yields ranging from 56.8% to 83.3%.

Techniques: Clinical Proteomics, Sequencing

Flow diagram depicting patient and sample selection for the comparison of BAL fluid mcfDNA sequencing with the Karius® test and standard of care testing.

Journal: medRxiv

Article Title: Microbial cell-free DNA sequencing of bronchoalveolar lavage fluid improves diagnostic yield and may add clinical utility in immunocompromised patients with severe pneumonia

doi: 10.1101/2025.11.05.25339543

Figure Lengend Snippet: Flow diagram depicting patient and sample selection for the comparison of BAL fluid mcfDNA sequencing with the Karius® test and standard of care testing.

Article Snippet: For each sample, the BAL fluid mcfDNA sequencing test report included the name of each identified organism, the number of microbial reads found for the organism, and the Karius® designation for the pathogenicity of the organism (see Definitions).

Techniques: Selection, Comparison, Sequencing

Additive diagnostic value of BAL fluid mcfDNA sequencing with the Karius® test (KT-BAL) compared to standard of care (SOC) testing in immunocompromised patients with pneumonia. A) Number of organisms across all samples identified by either SOC alone, KT-BAL alone, or both techniques, split by KT-BAL category. B) Organisms identified exclusively by KT-BAL across all samples, split by KT-BAL category.

Journal: medRxiv

Article Title: Microbial cell-free DNA sequencing of bronchoalveolar lavage fluid improves diagnostic yield and may add clinical utility in immunocompromised patients with severe pneumonia

doi: 10.1101/2025.11.05.25339543

Figure Lengend Snippet: Additive diagnostic value of BAL fluid mcfDNA sequencing with the Karius® test (KT-BAL) compared to standard of care (SOC) testing in immunocompromised patients with pneumonia. A) Number of organisms across all samples identified by either SOC alone, KT-BAL alone, or both techniques, split by KT-BAL category. B) Organisms identified exclusively by KT-BAL across all samples, split by KT-BAL category.

Article Snippet: For each sample, the BAL fluid mcfDNA sequencing test report included the name of each identified organism, the number of microbial reads found for the organism, and the Karius® designation for the pathogenicity of the organism (see Definitions).

Techniques: Diagnostic Assay, Sequencing

Patients for whom BAL fluid mcfDNA testing with the Karius® test (KT-BAL) identified Category One or Two organisms missed by standard of care (SOC) had significantly more cumulative intubation days compared to patients where KT-BAL and SOC were concordant for all Category One or Two organisms. Hospital length of stay, ICU length of stay, and ICU mortality were worse in the KT-BAL only group, but these differences were not significant (Mann-Whitney U test for continuous variables, Fisher’s exact test for mortality).

Journal: medRxiv

Article Title: Microbial cell-free DNA sequencing of bronchoalveolar lavage fluid improves diagnostic yield and may add clinical utility in immunocompromised patients with severe pneumonia

doi: 10.1101/2025.11.05.25339543

Figure Lengend Snippet: Patients for whom BAL fluid mcfDNA testing with the Karius® test (KT-BAL) identified Category One or Two organisms missed by standard of care (SOC) had significantly more cumulative intubation days compared to patients where KT-BAL and SOC were concordant for all Category One or Two organisms. Hospital length of stay, ICU length of stay, and ICU mortality were worse in the KT-BAL only group, but these differences were not significant (Mann-Whitney U test for continuous variables, Fisher’s exact test for mortality).

Article Snippet: For each sample, the BAL fluid mcfDNA sequencing test report included the name of each identified organism, the number of microbial reads found for the organism, and the Karius® designation for the pathogenicity of the organism (see Definitions).

Techniques: MANN-WHITNEY